Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 19Docetaxel 9atezolizumab 8Cetuximab 8Nivolumab 7cemiplimab 6Ipilimumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Drug Therapy 4spartalizumab 3palbociclib 3fludarabine 3durvalumab 3avelumab 3Trastuzumab 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Fulvestrant 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3Bortezomib 3Blood Specimen Collection 3seribantumab 2selpercatinib 2pazopanib 2motexafin gadolinium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × IFL protocol × Breast × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡